new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease

There are new concerns about using selegiline (Eldepryl) for patients with early Parkinson's disease.

A surprising British study suggests that adding selegiline to levodopa therapy doesn't slow the progression of Parkinson's...and might increase mortality.

But tell patients not to panic...many experts dispute these findings and say the study was flawed. They say that selegiline DOES help certain patients...by improving symptoms and having a levodopa-sparing effect.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote